Yes but we all have to accept that dilution coupled with a massive continual PR train has created a situation in such that catalysts outside of revenue/partner will not move PPS such as Orphan designation. Their aggressive PR strategy has definitely aided flippers and manipulators. They can not uplist with out revenue at this point it would be way too risky. You can not convince me wed sustain initial split value. Wed also ensure we remain a target for mass flipping on Nasdaq as well. New exchange same game buy at 4 sell at 4.80 rinse repeat. The ones proclaiming bring on the 50:1 split i bought at .04 have gone full tard.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links